CytoImmune to Participate in Upcoming April Investor Conferences

MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced that Christina Coughlin, M.D., Ph.D., chief executive officer, will participate in the following April investor conferences:

• Locust Walk Stem Cell Tx Conference in Partnership with Harvard Stem Cell Institute (formal presentation) on Monday, April 11, 2022, at 11:00 a.m. ET;
• Needham 21^st Annual Virtual Healthcare Conference’s “NK Therapeutics Panel” on Thursday, April 14, 2022, at 11:45 a.m. ET; and,
• Chardan Annual Genetic Medicines & Cell Therapy Manufacturing Summit (fireside chat) on Monday, April 25, 2022, at 9:00 a.m. ET.

About CytoImmune

CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the engineered cells to activate the patient’s immune system to eliminate cancer cells. The company is advancing a differentiated pipeline of off-the-shelf NK cell therapies, using proprietary, robust and well characterized NK cell expansion and engineering technologies that are designed to provide effector cell therapy with broad immune stimulation, to enable effective tumor killing in both solid tumors and hematologic malignancies. For more information, please visit Cytoimmune.com.